AMID Co., July 2010, Pages: 200
's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (1999, 2004
Future Science Ltd, Nov 2010, Pages: 179
significant current interest in DBS amongst bioanalysts, toxicologists, and pharmacokineticists who see the benefits of implementing DBS sampling in their drug development programs. Consequently, a large amount
Business Insights, April 2009, Pages: 159
development
Figure 6.14: The place of innovative technologies in early clinical safety assessment
Figure 6.15: Comparison of midazolam pharmacokinetics at microdose and therapeutic dose levels in the CREAM
Jain PharmaBiotech, Feb 2012, Pages: 345
of drugs at the discovery stage to avoid development of drugs that fail to reach their target site of action in the CNS.
Various strategies that have been used for manipulating the blood-brain barrier
Arrowhead Publishers, March 2007, Pages: 149
The clinical trials industry has clear potential for strong growth in the future, driven by technological and scientific advances. This trend is complemented by the development of new trial designs
John Wiley and Sons Ltd, Aug 2011, Pages: 530
information from leading researchers in the field addresses specific topics and techniques that are of interest in drug discovery, evaluation, and development.
A groundbreaking new guide to the applications
John Wiley and Sons Ltd, Jan 2011, Pages: 520
This book is a compilation of summarized analytical methods designed to serve the needs of pharmacologists, toxicologists, and other allied health professionals involved the development, use
